Survey Confirms Physician Interest in Peanut Allergy Immunotherapy
February 03, 2020 09:04 ET
|
Intrommune Therapeutics
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other...
Intrommune to Present at Biotech Showcase™ 2020
December 18, 2019 09:05 ET
|
Intrommune Therapeutics
New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics will attend and present at the upcoming Biotech Showcase™, which occurs during the annual J.P. Morgan Biotechnology...
Intrommune Participates in 2019 Food Allergy Fund Summit
November 26, 2019 15:41 ET
|
Intrommune Therapeutics
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment for peanut and other food allergies delivered...
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
November 07, 2019 10:00 ET
|
Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
September 16, 2019 14:25 ET
|
Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
September 13, 2019 09:05 ET
|
Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
September 05, 2019 15:20 ET
|
Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
August 21, 2019 14:41 ET
|
Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
May 17, 2019 13:25 ET
|
Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET
|
Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...